Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Thursday it has begun discussions with the U.S. government to launch ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

The health landscape sees pivots as companies adjust strategies: Bristol Myers and Pfizer offer discounts on Eliquis, Newcastle University's IVF technique prevents genetic diseases, and Juul's ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...